Moderna Inc. (MRNA)
Down 79%, Is Moderna Stock a Bad-News Buy on the Dip?
Moderna (MRNA 0.90%) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long.
Is Moderna Stock a No-Brainer Buy on the Sell-Off?
A bad seven-month stretch just got worse for Moderna (MRNA -1.96%). The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P.
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash
The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook
Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast
Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S. banks are also set for release this week.
Moderna slashes 2025 sales forecast, shares sink
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales of $3 billion to $3.1 billion, below the Street consensus of $3.3 billion.
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion.
Why Moderna Stock Just Crashed 21%
Moderna's (MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot.
Moderna Stock Heads for Worst Day Ever on Forecast Cut
Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.
Moderna Stock Heads for Worst-Ever Day After Reducing Revenue Forecast
Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.
Cramer's Stop Trading: Moderna
CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.
